Registry for Treatment of Upper Urinary Tract Tumours

NCT02281188 | Unknown

• 1 other identifier: Registry UTUC
• Study Type: observational
• Target: 2,451
• Locations: 1 country
• Sites: 1

Brief Summary

The aim of this registry is to evaluate the incidence, indications and outcomes of patients presenting with UTUC in relation to the different treatment modalities used.

Conditions

Upper Urinary Tract Tumours

Outcome Measures

Primary Outcomes (1)

• Recurrence rates for patients presenting with primary UTUC stratified for type of treatment

  Data collection will be divided into the following categories: Patient / tumour characteristics, assessment, treatment choice and intra-operative details, post-operative details and complications, and follow up. The following lists all categories and type of data to be gathered. Patient characteristics: demographics, risk factors, comorbidities and previous malignancies. Assessment: symptoms, imaging type, cytology, TNM staging. Treatment choice and intra-operative details: date, use of endoscopy, type of scopes, type of imaging enhancement, biopsies, results, neo adjuvant treatment specifications and treatment type. Intra-operative: date, duration, antibiotics, type of treatment, results. Post-operative: complications and Clavien-Dindo classification, instillation, adjuvant therapy, pathology. Follow up: date, status (e.g. alive without cancer, alive with cancer), recurrence, diagnostics performed, cystoscopy, cytology, results.

  10 years

Secondary Outcomes (1)

• Intra- and postoperative complications (including Clavien-Dindo classification)

  5 years

Eligibility Criteria

• Age: Up to 100 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Child (0-17), Adult (18-64), Older Adult (65+)
• Sampling Method: Probability Sample

Study Population

The study population comprises those patients presenting with (a) (suspected) primary UUT tumour(s) and are planned to undergo either nephroureterectomy, ureteroscopic diagnostics and/or ureteroscopic treatment, percutaneous treatment or adjuvant treatment in the participating centers.

You may qualify if:

• Is presenting with a suspected primary UTUC (any stage)
• Is scheduled for treatment of UUT tumour
• Has signed informed consent

Sponsors & Collaborators

• Clinical Research Office of the Endourological Society: lead

Study Sites (1)

Amsterdam UMC

Amsterdam, Netherlands

Location

Related Publications (7)

• Zhao H, Liu K, Crisci A, Te Slaa E, Habuchi T, Akand M, Ng CF, Laguna P, Teoh JY, de la Rosette J. Impact of smoking status at diagnosis on oncological outcomes of upper-tract urothelial carcinoma. Ther Adv Urol. 2025 Jun 28;17:17562872251352049. doi: 10.1177/17562872251352049. eCollection 2025 Jan-Dec.

  PMID: 40584958 DERIVED

• Liu K, Leung DK, Wong CH, Ko IC, Horuz R, Gontero P, Laguna P, de la Rosette J, Teoh JY. Influence of tumour location on the survival outcomes of upper tract urothelial carcinoma treated with radical nephroureterectomy. World J Urol. 2025 May 3;43(1):261. doi: 10.1007/s00345-024-05432-0.

  PMID: 40317391 DERIVED

• Liu K, Wong CH, Zhao H, Ng CF, Teoh JY, Laguna P, de la Rosette J. Impact of Antiaggregant and Anticoagulant Medications on Perioperative Complications in Upper Tract Urothelial Carcinoma. Eur Urol Open Sci. 2025 Mar 20;75:1-6. doi: 10.1016/j.euros.2025.02.007. eCollection 2025 May.

  PMID: 40206439 DERIVED

• Baard J, Cormio L, Dasgupta R, Maruzzi D, Rais-Bahrami S, Serrano A, Geavlete B, Giannakopoulos S, de la Rosette J, Laguna P. Unveiling the challenges of UTUC biopsies and cytology: insights from a global real-world practice study. World J Urol. 2024 Mar 20;42(1):177. doi: 10.1007/s00345-024-04866-w.

  PMID: 38507109 DERIVED

• Baard J, Shariat SF, Roupret M, Yoshida T, Saita A, Saltirov I, Burgos JR, Celik O, de la Rosette J, Laguna P. Adherence to guideline recommendations in the management of upper tract urothelial carcinoma: an analysis of the CROES-UTUC registry. World J Urol. 2022 Nov;40(11):2755-2763. doi: 10.1007/s00345-022-04168-z. Epub 2022 Oct 5.

  PMID: 36197507 DERIVED

• Baard J, Cormio L, Cavadas V, Alcaraz A, Shariat SF, de la Rosette J, Laguna MP. Contemporary patterns of presentation, diagnostics and management of upper tract urothelial cancer in 101 centres: the Clinical Research Office of the Endourological Society Global upper tract urothelial carcinoma registry. Curr Opin Urol. 2021 Jul 1;31(4):354-362. doi: 10.1097/MOU.0000000000000899.

  PMID: 34009177 DERIVED

• Baard J, Celebi M, de la Rosette J, Alcaraz A, Shariat S, Cormio L, Cavadas V, Laguna MP. Evaluation of Patterns of Presentation, Practice, and Outcomes of Upper Tract Urothelial Cancer: Protocol for an Observational, International, Multicenter, Cohort Study by the Clinical Research Office of the Endourology Society. JMIR Res Protoc. 2020 Jan 24;9(1):e15363. doi: 10.2196/15363.

  PMID: 32012106 DERIVED

Related Links

• Related Info

Study Officials

• Jean de la Rosette

  Clinical Research Office of the Endourological Society

  STUDY CHAIR

Study Design

• Study Type: observational
• Observational Model: COHORT
• Time Perspective: PROSPECTIVE
• Target Duration: 5 Years
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: September 26, 2014
• First Posted: November 3, 2014
• Study Start: November 1, 2014
• Primary Completion: March 12, 2019
• Study Completion: March 1, 2024
• Last Updated: December 14, 2020

Record last verified: 2020-12

Locations

NL (1)